Internal Medicine Department
Hematology Division

Michael A. Pulsipher, MD

Email:    michael.pulsipher@hsc.utah.edu

Education:

1986 – 1990    M.D., Stanford University School of Medicine, Palo Alto, California

1980 – 1986    B.A. in Biology & Chemistry, Brigham Young University, Provo, Utah

Training:

1993 – 1996    Fellow in Pediatric Hematology/Oncology, Children's Hospital/Dana Farber Cancer Institute, Boston, Massachusetts

1991 – 1993    Resident in Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

1990 – 1991    Intern in Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

Research Interests:

Non-Myeloablative/Reduced Intensity Bone Marrow Transplantation in Adults and Pediatrics
Hematopoietic Cell Transplantation for Pediatric Acute Lymphoid Leukemia
Hematopoietic Cell Donor Safety
Hematopoietic Cell Transplantation for Non-malignant Disorders

Recent Publications

  1. Baron F, Storb R, Storer BE, Maris MB, Niederwieser D, Shizuru JA, Chauncey TR, Bruno B, Forman SJ, McSweeney PA, Maziarz RT, Pulsipher MA, Agura ED, Wade J, Sorror M, Maloney DG, Sandmaier BM. (2006). Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol, 24(25), 4150-7.
  2. Wendland MM, Asch JD, Pulsipher MA, Thomson JW, Shrieve DC, Gaffney DK. (2006). The impact of involved field radiation therapy for patients receiving high-dose chemotherapy followed by hematopoietic progenitor cell transplant for the treatment of relapsed or refractory Hodgkin disease. Am J Clin Oncol, 29(2), 189-95.
  3. Grupp SA, Frangoul H, Wall D, Pulsipher MA, Levine JE, Schultz KR. (2006). Use of G-CSF in matched sibling donor pediatric allogeneic transplantation: a consensus statement from the Children's Oncology Group (COG) Transplant Discipline Committee and Pediatric Blood and Marrow Transplant Consortium (PBMTC) Executive Committee. Pediatr Blood Cancer, 46(4), 414-21.
  4. Pulsipher MA, Nagler A, Iannone R, Nelson RM(2006). Weighing the risks of G-CSF administration, leukopheresis, and standard marrow harvest: ethical and safety considerations for normal pediatric hematopoietic cell donors. Pediatr Blood Cancer, 46(4), 422-33.
  5. Eapen M, Rubinstein P, Zhang MJ, Camitta BM, Stevens C, Cairo MS, Davies SM, Doyle JJ, Kurtzberg J, Pulsipher MA, Ortega JJ, Scaradavou A, Horowitz MM, Wagner JE. (2006). Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months. J Clin Oncol, 24(1), 145-51.
  6. Baron F, Maris MB, Storer BE, Sandmaier BM, Stuart MJ, McSweeney PA, Radich JP, Pulsipher MA, Agura ED, Chauncey TR, Maloney DG, Shizuru JA, Storb R. (2005). HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia. Biol Blood Marrow Transplant, 11(4), 272-9.
  7. Choi SW, Boxer LA, Pulsipher MA, Roulston D, Hutchinson RJ, Yanik GA, Cooke KR, Ferrara JL, Levine JE. (2005). Stem cell transplantation in patients with severe congenital neutropenia with evidence of leukemic transformation. Bone Marrow Transplant, 35(5), 473-7.
  8. Pulsipher MA, Levine JE, Hayashi RJ, Chan KW, Anderson P, Duerst R, Osunkwo I, Fisher V, Horn B, Grupp SA. (2005). Safety and efficacy of allogeneic PBSC collection in normal pediatric donors: the pediatric blood and marrow transplant consortium experience (PBMTC) 1996-2003. Bone Marrow Transplant, 35(4), 361-7.
  9. Maris MB, Sandmaier BM, Storer BE, Chauncey T, Stuart MJ, Maziarz RT, Agura E, Langston AA, Pulsipher M, Storb R, Maloney DG. (2004). Allogeneic Hematopoietic Cell Transplantation after Fludarabine and 2 Gy Total Body Irradiation for Relapsed and Refractory Mantle Cell Lymphoma. Blood.
  10. Pulsipher MA. (2004). Treatment of CML in pediatric patients: should imatinib mesylate (STI-571, Gleevec) or allogeneic hematopoietic cell transplant be front-line therapy? Pediatr Blood Cancer, 43(5), 523-33.
  11. Pulsipher MA, Adams RH, Asch J, Petersen FB. (2004). Successful treatment of JMML relapsed after unrelated allogeneic transplant with cytoreduction followed by DLI and interferon-alpha: evidence for a graft-versus-leukemia effect in non-monosomy-7 JMML. Bone Marrow Transplant, 33(1), 113-5.